Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEF 0117

Next Previous
Drug Profile

AEF 0117

Alternative Names: AEF-0117

Latest Information Update: 13 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aelis Farma
  • Developer Aelis Farma; Columbia University; National Institute of Drug Abuse; New York State Psychiatric Institute
  • Class Drug withdrawal therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Substance-related disorders

Most Recent Events

  • 27 Feb 2026 Aelis Farma in collaboration with National Institute on Drug Abuse (NIDA) withdraws a phase I drug drug interaction trial in Substance-related disorders (In volunteers) prior to enrolment (PO) (NCT06395688)
  • 22 Jul 2024 Aelis Farma completes the phase IIb SICA 2 trial for substance related disorders in USA (PO) (NCT05322941)
  • 29 Apr 2024 Aelis Farma in collaboration with National Institute on Drug Abuse (NIDA) plans a phase I trial in Substance-related disorders (In volunteers) in June 2024 (PO) (NCT06395688)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top